In the production of immediate-release aminocaproic acid tablets, the 500 mg and 1000 mg dose strengths impose a high drug-loading boundary in which the API fraction of a compressed core cannot fall far below 65% w/w for the 1000 mg strength without producing a core mass above 1500 mg, complicating tablet dimensions and swallowability. A representative 500 mg core with total mass 700 mg contains aminocaproic acid 71.4% w/w, microcrystalline cellulose 20.0% w/w, crospovidone 4.0% w/w, povidone K30 3.0% w/w, colloidal silicon dioxide 1.0% w/w, and magnesium stearate 0.6% w/w; a 1000 mg core with total mass 1450 mg reduces the API fraction to 69.0% w/w to accommodate additional binder and disintegrant for adequate compact strength. The blend is granulated in a high-shear granulator with purified water or an aqueous povidone solution, dried in a fluid-bed dryer at inlet air temperature 55–65 °C until loss-on-drying reaches 1.0–2.0% w/w, and milled through a 0.8 mm screen before final bin blending. Compression on a 45-station rotary press for 500 mg tablets uses oval tooling with main compression 10–15 kN, yielding breaking force 80–120 N; the 1000 mg dose uses caplet tooling with main compression 18–25 kN, yielding breaking force 120–170 N. Field batches on the 45-station press have shown punch sticking when main compression exceeds 25 kN and the lubricant level is below 0.5% w/w; precompression below 6 kN increases capping frequency. Friability measured per USP 1216 remains at or below 1.0% after 100 rotations, and disintegration per USP 701 in purified water at 37±2 °C is normally below 15 min unless granule overwetting produces a dense film on the tablet surface. Dissolution testing per USP 711 uses the medium and Q value specified in the Aminocaproic Acid Tablets monograph, with content uniformity evaluated according to USP 905. Finished presentations include 500 mg and 1000 mg immediate-release tablets in unit-dose blisters and HDPE bottles with desiccant.

For encapsulation into hard gelatin or HPMC shells, aminocaproic acid is delivered as a densified granule rather than as the as-received powder because the high fill weight required for a 500 mg dose in a size 00 shell creates insufficient headspace for low-bulk-density powder and produces excessive weight variation on dosator-type filling machines. A fill mass of 600 mg yields an API fraction of 83.3% w/w, with pregelatinized starch 11.7% w/w, crospovidone 3.0% w/w, colloidal silicon dioxide 1.0% w/w, and magnesium stearate 1.0% w/w. Dry granulation is preferred over aqueous wet granulation for capsule-dedicated granules because water can recrystallize the water-soluble API on the granule surface and slow dissolution. A roller compactor with gap 1.2–1.5 mm and roll pressure 40–60 bar produces ribbons that are milled through a 0.8 mm screen; the resulting granules are blended in a bin blender for 15 min and filled into size 00 hard gelatin or HPMC shells on a dosing-disc or tamping-pin capsule filler with target fill weight control of ±3.0%. Powder feed is conditioned to 20–25 °C and 35–50% RH; pre-drying at 40–50 °C is required if ambient RH exceeds 60% because moisture uptake above 1.5% w/w causes powder adhesion to tamping pins and increases capsule weight variability. Compliance testing includes USP 905 for weight variation, USP 711 for dissolution using the monograph medium, and USP 701 for disintegration if required. Finished presentation is a 500 mg hard capsule in HDPE bottles with desiccant and child-resistant closure.

When a Single-Dose Granule Presentation Is Specified for Nasogastric or Sprinkled Administration

Published data for this specific finished presentation is limited; when a granule presentation is prepared or compounded for patients unable to swallow intact tablets or capsules, aminocaproic acid is formulated as a single-dose sachet intended for dispersion in water immediately before administration through a nasogastric tube or for sprinkling onto soft food. A 1000 mg dose in a total sachet fill mass of 1150 mg contains 87.0% w/w aminocaproic acid, 8.7% w/w mannitol, 2.6% w/w povidone K30, 1.2% w/w crospovidone, and 0.5% w/w colloidal silicon dioxide. The granulation route uses purified water in a low-shear mixer, followed by fluid-bed drying at inlet air 50–60 °C to a loss-on-drying of 0.8–1.5% w/w and sieving through a 0.5–1.0 mm mesh to retain granules in a flowable size range. The granules are filled into foil laminate sachets under 30–40% RH; overfilling above 1150 mg must be avoided because dispersion through a 12 Fr nasogastric tube may clog when the granule-to-water ratio exceeds 100 mg/mL in the absence of published dispersion data for higher concentrations. Batch release relies on USP 795 for non-sterile compounding when prepared in small quantities, USP 711 or a suitable dispersion assessment for reconstituted dose delivery, and ICH Q3D elemental impurity limits where the API source is changed. The terminal product is a single-dose sachet of 1000 mg aminocaproic acid granules for direct sprinkle or nasogastric administration.

Oral Solution Preservative Efficacy and Dosing Accuracy at 250 mg/mL

The oral solution presentation is a clear aqueous vehicle containing 250 mg aminocaproic acid per mL, equivalent to 25.0% w/v; this concentration is specified in the Aminocaproic Acid Oral Solution monograph and is used for adult and pediatric dosing when a calibrated oral syringe or dosing cup replaces tablet splitting. The API is dissolved in purified water, the pH is adjusted to 6.0–7.0 with hydrochloric acid or sodium hydroxide, and the solution is filtered through a 0.45 µm membrane before filling into multi-dose bottles. If a preservative system is present, antimicrobial effectiveness testing per USP 51 must demonstrate log reduction at 7, 14, and 28 days for challenge organisms including Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis. pH is verified per USP 791, and stability studies under 21 CFR 211.166 monitor assay, pH, and preservative content over the labeled storage period. Dosing accuracy is evaluated by deliverable volume testing from the marketed bottle and closure system; any adsorption of preservative to the closure or loss of aminocaproic acid due to oxidation is an out-of-specification signal requiring reformulation. The finished product is a 250 mg/mL oral solution in multi-dose HDPE or glass bottles with a calibrated dosing device.

What Filtration and Filling Boundaries Govern a 250 mg/mL Injectable Presentation?

The injectable presentation is a single-dose aqueous solution containing 250 mg aminocaproic acid per mL (25.0% w/v), supplied as 5 g in 20 mL Type I glass vials. The solution is prepared in Water for Injection, adjusted to pH 6.0–7.0 per the Aminocaproic Acid Injection monograph, and passed through a 0.22 µm PVDF or PES membrane filter before aseptic filling. Bioburden before sterile filtration is controlled to not more than 10 CFU/100 mL in compliance with EU GMP Annex 1 expectations; post-use filter integrity is verified by bubble point or diffusion test with a minimum bubble point of 3200 mbar for a 0.22 µm PVDF membrane. Aseptic filling occurs in Grade A critical zones with Grade B background, with Grade A airborne particulate limits of ≤3520 particles ≥0.5 µm per m³ and ≤20 particles ≥5 µm per m³ at rest. If terminal steam sterilization is used instead of aseptic filtration, the cycle must achieve a physical lethality F0 of at least 12 min at 121.1 °C per ISO 17665, and post-sterilization pH shift must not exceed 0.2 units with assay loss not more than 2.0%. The undiluted solution is hyperosmotic with calculated osmolarity above 1800 mOsm/L; this limits direct intravenous push administration and requires dilution before infusion. Particulate matter is tested per USP 788 for small-volume injections, visible particles per USP 790, sterility per USP 71, and bacterial endotoxins per USP 85. Finished presentation is a 5 g/20 mL single-dose vial.

Aseptic dilution of the 250 mg/mL injectable solution into polyolefin or PVC infusion bags produces admixtures of 5 mg/mL to 20 mg/mL for continuous or intermittent intravenous infusion. A 5 g dose (20 mL) diluted in 250 mL of 0.9% sodium chloride yields 20 mg/mL; the same dose diluted in 1000 mL yields 5 mg/mL. Preparation is performed in an ISO Class 5 hood under USP 797 compounded sterile preparation requirements, with aseptic transfer, closed-system dosing verification, and visual inspection for particulate matter or discoloration before administration. Compatibility data support dilution in 0.9% sodium chloride and 5% dextrose; admixtures prepared in PVC or polyolefin containers should be used within the time specified in the approved labeling or institutional stability protocol, because published compatibility data for all container types and concentrations are limited. Combination with strong oxidizing agents or highly alkaline injections is avoided because oxidative degradation and pH shift may produce subvisible particles. The terminal product is a ready-to-administer intravenous infusion of 5 mg/mL to 20 mg/mL aminocaproic acid.